A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United States

Colorado Blood Cancer Institute, Denver, Colorado

Florida Cancer Specialists, Sarasota, Florida

University of North Carolina, Chapel Hill, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus, Ohio